TISIDB

Summary
Symbol	CDX2
Name	caudal type homeobox 2
Aliases	CDX3; caudal type homeo box transcription factor 2; CDX-3/AS; caudal type homeobox transcription factor 2; c ......
Chromosomal Location	13q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Nucleus.
Domain	PF04731 Caudal like protein activation region PF00046 Homeobox domain
Function	Involved in the transcriptional regulation of multiple genes expressed in the intestinal epithelium. Important in broad range of functions from early differentiation to maintenance of the intestinal epithelial lining of both the small and large intestine. Binds preferentially to methylated DNA (PubMed:28473536).

> Gene Ontology [ TOP ]
Biological Process	GO:0001701 in utero embryonic development GO:0001756 somitogenesis GO:0001824 blastocyst development GO:0001825 blastocyst formation GO:0001829 trophectodermal cell differentiation GO:0001890 placenta development GO:0001892 embryonic placenta development GO:0002065 columnar/cuboidal epithelial cell differentiation GO:0003002 regionalization GO:0007034 vacuolar transport GO:0007041 lysosomal transport GO:0007163 establishment or maintenance of cell polarity GO:0007389 pattern specification process GO:0008333 endosome to lysosome transport GO:0009798 axis specification GO:0009948 anterior/posterior axis specification GO:0009952 anterior/posterior pattern specification GO:0014807 regulation of somitogenesis GO:0016197 endosomal transport GO:0019827 stem cell population maintenance GO:0035019 somatic stem cell population maintenance GO:0035088 establishment or maintenance of apical/basal cell polarity GO:0035282 segmentation GO:0045197 establishment or maintenance of epithelial cell apical/basal polarity GO:0045995 regulation of embryonic development GO:0048565 digestive tract development GO:0048568 embryonic organ development GO:0048608 reproductive structure development GO:0055123 digestive system development GO:0060575 intestinal epithelial cell differentiation GO:0060711 labyrinthine layer development GO:0061053 somite development GO:0061245 establishment or maintenance of bipolar cell polarity GO:0061458 reproductive system development GO:0098727 maintenance of cell number
Molecular Function	GO:0000980 RNA polymerase II distal enhancer sequence-specific DNA binding GO:0001158 enhancer sequence-specific DNA binding GO:0001227 transcriptional repressor activity, RNA polymerase II transcription regulatory region sequence-specific binding GO:0003714 transcription corepressor activity GO:0035326 enhancer binding
Cellular Component	GO:0000793 condensed chromosome GO:0000794 condensed nuclear chromosome GO:0017053 transcriptional repressor complex

> KEGG and Reactome Pathway [ TOP ]
KEGG	-
Reactome	R-HSA-1266738: Developmental Biology R-HSA-400508: Incretin synthesis, secretion, and inactivation R-HSA-392499: Metabolism of proteins R-HSA-2892245: POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation R-HSA-2980736: Peptide hormone metabolism R-HSA-381771: Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1) R-HSA-452723: Transcriptional regulation of pluripotent stem cells

> KEGG and Reactome Pathway

[ TOP ]

KEGG

Reactome

R-HSA-1266738: Developmental Biology
R-HSA-400508: Incretin synthesis, secretion, and inactivation
R-HSA-392499: Metabolism of proteins
R-HSA-2892245: POU5F1 (OCT4), SOX2, NANOG repress genes related to differentiation
R-HSA-2980736: Peptide hormone metabolism
R-HSA-381771: Synthesis, secretion, and inactivation of Glucagon-like Peptide-1 (GLP-1)
R-HSA-452723: Transcriptional regulation of pluripotent stem cells

Summary
Symbol	CDX2
Name	caudal type homeobox 2
Aliases	CDX3; caudal type homeo box transcription factor 2; CDX-3/AS; caudal type homeobox transcription factor 2; c ......
Chromosomal Location	13q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between CDX2 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining

[ TOP ]

Literatures describing the relation between CDX2 and anti-tumor immunity in human cancer.

PMID	Cancer type	Relation to immunity	Evidence sentences
27813511	Colorectal Cancinoma	Promote immunity	Aberrantly expressed CD274 allows tumor cells to evade host immune system and is considered to be a mechanism of adaptive immune resistance. Moreover, colorectal carcinomas characterized by lack of CDX2 and prominent expression of ALCAM frequently (71%) showed CD274 positivity. This might suggest association of CD274 expression with 'stem-like' phenotype.

Summary
Symbol	CDX2
Name	caudal type homeobox 2
Aliases	CDX3; caudal type homeo box transcription factor 2; CDX-3/AS; caudal type homeobox transcription factor 2; c ......
Chromosomal Location	13q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of CDX2 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	CDX2
Name	caudal type homeobox 2
Aliases	CDX3; caudal type homeo box transcription factor 2; CDX-3/AS; caudal type homeobox transcription factor 2; c ......
Chromosomal Location	13q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of CDX2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.645	0.296
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.703	0.481
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-0.572	0.615
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0	1
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0	1
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0	1
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0	1
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0	1
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.335	0.316

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of CDX2 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	7.1	0	7.1	0.452
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	10	0	10	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	5.9	-5.9	0.447
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	16.7	-16.7	0.429
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	11.1	0	11.1	0.36
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	25	0	25	0.364
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	CDX2
Name	caudal type homeobox 2
Aliases	CDX3; caudal type homeo box transcription factor 2; CDX-3/AS; caudal type homeobox transcription factor 2; c ......
Chromosomal Location	13q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of CDX2. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	CDX2
Name	caudal type homeobox 2
Aliases	CDX3; caudal type homeo box transcription factor 2; CDX-3/AS; caudal type homeobox transcription factor 2; c ......
Chromosomal Location	13q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of CDX2. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by CDX2. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	CDX2
Name	caudal type homeobox 2
Aliases	CDX3; caudal type homeo box transcription factor 2; CDX-3/AS; caudal type homeobox transcription factor 2; c ......
Chromosomal Location	13q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of CDX2. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	CDX2
Name	caudal type homeobox 2
Aliases	CDX3; caudal type homeo box transcription factor 2; CDX-3/AS; caudal type homeobox transcription factor 2; c ......
Chromosomal Location	13q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of CDX2 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	CDX2
Name	caudal type homeobox 2
Aliases	CDX3; caudal type homeo box transcription factor 2; CDX-3/AS; caudal type homeobox transcription factor 2; c ......
Chromosomal Location	13q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between CDX2 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	CDX2
Name	caudal type homeobox 2
Aliases	CDX3; caudal type homeo box transcription factor 2; CDX-3/AS; caudal type homeobox transcription factor 2; c ......
Chromosomal Location	13q12.2
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting CDX2 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse CDX2